Ignite Creation Date:
2024-07-17 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06479720
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-06-23
Brief Title:
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
Sponsor:
Mackay Memorial Hospital
Organization:
Mackay Memorial Hospital
Study Overview
Official Title:
Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder
Detailed Description:
Women with detrusor overactivity who were refractory to anti-muscarinics or mirabegron were enrolled for prospective study Patients were divided into three groups combined pharmacotherapy with solifenacin and mirabegron solifenacin with vaginal estrogen cream and mirabegron with vaginal estrogen cream Incontinence-related symptoms distress and impact on quality of life were evaluated by short form of Urinary Distress Inventory UDI-6 Incontinence Impact Questionnaire IIQ-7 and Overactive Bladder Symptom Score OABSS Objective outcomes include changes from baseline in episodes of daily micturition urgency urinary incontinence and nocturia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None